Antibiotic candidate, Plazomicin, achieves positive results in Phase 3 clinical trials
by Press Release from Outbreak News Today on (#2516V)
Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that its lead product candidate, plazomicin, met the objective of non-inferiority compared to meropenem for the U.S. Food and Drug Administration (FDA) and achieved superiority for the European Medicines Agency (EMA) primary efficacy endpoints in the Phase 3 ["]
The post Antibiotic candidate, Plazomicin, achieves positive results in Phase 3 clinical trials appeared first on Outbreak News Today.